Table 2. Association of MPO+ and CD15+ low and high immune cell density with clinicopathological features in CRC.
| MPO− | MPO+ | p-value | CD15 – | CD15+ | p-value | ||||||
| N = 1047 | (85.4%) | N = 178 | (14.5%) | N = 1062 | (89.2%) | N = 129 | (10.8%) | ||||
| Age | years | 71 | (30–96) | 73 | (37–96) | 0.04 | 71 | (30–96) | 71 | (38–96) | 0.45 |
| Tumor diameter | mm | 49 | (8–120) | 45 | (4–170) | 0.84 | 45 | (4–160) | 45 | (8–170) | 0.99 |
| Gender | Female | 546 | (52.1) | 90 | (50.6) | 558 | (52) | 70 | (54.3) | 0.64 | |
| Male | 501 | (47.9) | 88 | (49.4) | 0.75 | 515 | (48) | 59 | (45.7) | ||
| Tumor location | Left-sided | 674 | (64.4) | 117 | (65.7) | 0.86 | 677 | (63.1) | 95 | (73.6) | 0.018 |
| Right-sided | 361 | (34.5) | 60 | (33.7) | 385 | (35.9) | 32 | (24.8) | |||
| Histologic subtype | Mucinous | 86 | (8.2) | 16 | (9) | 0.66 | 97 | (9) | 7 | (5.4) | 0.19 |
| Non-mucinous | 955 | (91.2) | 158 | (88.8) | 965 | (89.9) | 122 | (94.6) | |||
| pT stage | pT1–2 | 182 | (17.4) | 48 | (27) | 0.007 | 190 | (17.7) | 41 | (31.8) | 0.0004 |
| pT3–4 | 833 | (79.6) | 129 | (72.5) | 857 | (79.9) | 87 | (67.4) | |||
| pN stage | pN0 | 527 | (50.3) | 101 | (56.7) | 0.16 | 536 | (50) | 72 | (55.8) | 0.35 |
| pN1-2 | 479 | (45.7) | 72 | (40.4) | 494 | (46) | 55 | (42.6) | |||
| Tumor grade | G1-2 | 894 | (85.4) | 146 | (82) | 0.224 | 907 | (84.5) | 110 | (85.3) | 0.68 |
| G3 | 129 | (12.3) | 28 | (15.7) | 138 | (12.9) | 18 | (14) | |||
| Vascular invasion | Absent | 740 | (70.7) | 133 | (74.7) | 0.27 | 754 | (70.3) | 102 | (79.1) | 0.07 |
| Present | 283 | (27) | 41 | (23) | 291 | (27.1) | 26 | (20.2) | |||
| Tumor border | Pushing | 385 | (36.8) | 75 | (42.1) | 0.178 | 404 | (37.7) | 45 | (34.9) | 0.44 |
| Infiltrating | 637 | (60.8) | 99 | (55.6) | 640 | (59.6) | 83 | (64.3) | |||
| PTL inflammation | Absent | 819 | (78.2) | 132 | (74.2) | 0.224 | 835 | (77.8) | 97 | (75.2) | 0.3 |
| Present | 205 | (19.6) | 42 | (23.6) | 211 | (19.7) | 31 | (24) | |||
| Local recurrence | Absent | 212 | (20.2) | 54 | (30.3) | 0.031 | 241 | (22.5) | 26 | (20.2) | 0.03 |
| Present | 162 | (15.5) | 23 | (12.9) | 180 | (16.8) | 8 | (6.2) | |||
| Distant metastasis | Absent | 304 | (29) | 69 | (38.8) | 0.108 | 343 | (32) | 32 | (24.8) | 0.08 |
| Present | 75 | (7.2) | 9 | (5.1) | 84 | (7.8) | 2 | (1.6) | |||
| Microsatellite stability | Deficient | 159 | (15.2) | 35 | (19.7) | 0.161 | 167 | (15.6) | 24 | (18.6) | 0.45 |
| Proficient | 888 | (86.1) | 143 | (13.9) | 729 | (67.9) | 88 | (68.2) | |||
| 5-year survival rate | (95%CI) | 55.6 | (52.4–59) | 68.5 | (61.3–76.5) | 0.0009 | 56.8 | (53.6–60.2) | 63.6 | (55.1–73.4) | 0.033 |
*
percentage may not add to 100% due to missing values of same variables; variables are indicated as absolute numbers, %, median or range; age and tumor size were evaluated using the Kruskal-Wallis test. Gender, anatomical site, T stage, N stage, grade, vascular invasion, and tumor border configuration were analyzed using the χ2 test. Survival analysis was performed using the Kaplan-Meier method.